Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection

Wis Med J. 1991 Apr;90(4):161-5.

Abstract

Zidovudine is the only anti-retroviral drug approved by the FDA for treatment of HIV infection. We have examined the clinical and laboratory efficacy of this drug for 4 years in a cohort of HIV-infected patients from Wisconsin. Overall, we have found that individuals with AIDS will have at least 1 year of symptom reduction while on the drug. Those with asymptomatic HIV infection tolerate the drug and none have progressed to AIDS in the 4 years of study. Zidovudine is an important component in the treatment of HIV infection.

Publication types

  • Clinical Trial

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • Adult
  • CD4-Positive T-Lymphocytes
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • Humans
  • Leukocyte Count
  • Male
  • Middle Aged
  • Zidovudine / administration & dosage
  • Zidovudine / therapeutic use*
  • beta 2-Microglobulin / analysis

Substances

  • beta 2-Microglobulin
  • Zidovudine